Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Macrophage Reprogramming Agent, exoASO-STAT6 (CDK-004), in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Either Primary Gastric Cancer or Colorectal Cancer (CRC)

NCT05375604 is registered in ClinicalTrials.gov with Codiak BioSciences as lead sponsor.

NCT NCT05375604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05375604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Macrophage Reprogramming Agent, exoASO-STAT6 (CDK-004), in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Either Primary Gastric Cancer or Colorectal Cancer (CRC)
Lead sponsor
Codiak BioSciences
Phase
Phase 1
Overall status
Terminated
Start date
June 28, 2022
Completion date
May 30, 2023
Enrollment
9 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma (hcc), colorectal cancer metastatic to liver, gastric cancer metastatic to liver